Ribomic Inc.
Notice on Progress of Subject Enrollment in Domestic Phase III Clinical Trial of Osteogenesis Imperfecta Treatment (umedaptanib pegol) (WAKABA Study)
Enrollment of two additional subjects completed in the domestic Phase III trial (WAKABA) using the new drug ume daptanib pegol, bringing total to three. Trial conducted at 16 sites with patient enrollment proceeding as planned. No impact on the FY2027 full-year results.
Key Figures
- Cumulative subject registrations: 3 cases
- New registrations: 2 cases
- Date of completion of clinical trial framework setup: 2026-08-24
AI要約
Section Heading
Progress report on the domestic Phase III clinical trial of the osteogenesis imperfecta treatment ume daptanib pegol (WAKABA study). Two additional subject registrations have been completed, bringing the cumulative total to three. The target is 16 registrations, and trial sites were fully prepared as of August 24, 2026. The study is progressing as planned, and enrollment will continue in coordination with the trial institutions. No financial impact is expected for the FY2027 full-year results.
Section 2 Heading
Umedaptanib pegol is an aptamer that inhibits FGF2 and is expected to directly influence the pathogenesis of osteogenesis imperfecta. It has been designated as an orphan drug, and further trial progress may affect the development roadmap. Investors should monitor the timing of safety and efficacy data acquisition at trial completion and the accompanying funding plans.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
